

Bielasz Jennifer Kathleen
Form 3
March 17, 2011

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Bielasz Jennifer Kathleen
(Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)
03/15/2011

3. Issuer Name and Ticker or Trading Symbol

ARENA PHARMACEUTICALS INC [ARNA]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

____ Director ____ 10% Owner
__X__ Officer ____ Other
(give title below) (specify below)
Sr. Dir. of Accounting & Cont.

C/O ARENA
PHARMACEUTICALS,
INC.,Â 6166 NANCY RIDGE
DRIVE

(Street)

SAN DIEGO,Â CAÂ 92121

(City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
__X__ Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Common Stock

7,666

D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Edgar Filing: Bielasz Jennifer Kathleen - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	Â <u>(1)</u>	01/15/2012	Common Stock	2,500	\$ 12.25	D	Â
Employee Stock Option (right to buy)	Â <u>(2)</u>	07/19/2012	Common Stock	5,000	\$ 11.31	D	Â
Employee Stock Option (right to buy)	Â <u>(3)</u>	01/18/2014	Common Stock	5,000	\$ 6	D	Â
Employee Stock Option (right to buy)	Â <u>(4)</u>	10/08/2014	Common Stock	2,500	\$ 4.41	D	Â
Employee Stock Option (right to buy)	Â <u>(5)</u>	01/17/2015	Common Stock	4,500	\$ 6.16	D	Â
Employee Stock Option (right to buy)	Â <u>(6)</u>	01/20/2016	Common Stock	3,000	\$ 16.8	D	Â
Employee Stock Option (right to buy)	Â <u>(7)</u>	07/28/2016	Common Stock	4,000	\$ 10.52	D	Â
Employee Stock Option (right to buy)	Â <u>(8)</u>	02/26/2017	Common Stock	6,500	\$ 13.5	D	Â
Employee Stock Option (right to buy)	Â <u>(9)</u>	03/03/2018	Common Stock	6,000	\$ 6.99	D	Â
Employee Stock Option (right to buy)	Â <u>(10)</u>	03/17/2019	Common Stock	6,000	\$ 4.01	D	Â
Employee Stock Option (right to buy)	Â <u>(11)</u>	03/17/2020	Common Stock	9,000	\$ 3.25	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bielasz Jennifer Kathleen C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO,Â CAÂ 92121	Â	Â	Â Sr. Dir. of Accounting & Cont.	Â

Signatures

Adam S. Chinnock, as
Attorney-in-Fact

03/17/2011

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The options vested in four equal annual installments beginning on January 15, 2003.
- (2) The options vested in four equal annual installments beginning on July 19, 2003.
- (3) The options vested in four equal annual installments beginning on June 1, 2004.
- (4) The options vested in four equal annual installments beginning on October 8, 2005.
- (5) The options were originally for 6,000 shares of common stock, and they vested in four equal annual installments beginning on June 1, 2005. The holder exercised options to purchase 1,500 shares of common stock.
- (6) The options vested in four equal annual installments beginning on January 20, 2007.
- (7) The options vested in four equal annual installments beginning on July 28, 2007.
- (8) The options vested in four equal annual installments beginning on February 26, 2008.
- (9) The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 3, 2009, the second installment became exercisable on March 3, 2010, the third installment became exercisable on March 3, 2011, and the fourth installment vests on March 3, 2012.
- (10) The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 17, 2010, the second installment vests on March 17, 2011, the third installment vests on March 17, 2012, and the fourth installment vests on March 17, 2013.
- (11) The options vest in four equal annual installments beginning on March 17, 2011, and are exercisable once vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.